Pacgen Biopharmaceuticals - Publications & Presentations

By: Pacgen Biopharmaceuticals  09-12-2011

Publications & Presentations


Poster Presentations

Eva J. Helmerhorst, Frank G Oppenheim, Lewis Choi, David Cheng, Neil E. Reiner ‚“Evaluation of a New Host-Derived Synthetic antifungal Peptide (PAC-113) in the Treatment of Oral Candidiasis“ presented at the 5th International Meeting on Antimicrobial Chemotherapy in Clinical Practice (ACCP), November 25-17, 2007.  Portofino, Italy.

Contact Pacgen Biopharmaceuticals


Print this page

Other products and services from Pacgen Biopharmaceuticals


Pacgen Biopharmaceuticals - Product Pipeline: G31P

In conditions such as ARDS where over-recruitment of neutrophils is part of the disease process, PAC-G31P is expected to block the receptors, overcome the excessive alarm signal, and restore a level of neutrophil recruitment that is appropriate to respond to the lung injury or infection.


Pacgen Biopharmaceuticals - Product Pipeline: Pipeline

The Phase IIb study, which involved over 200 seropositive HIV patients, demonstrated that PAC-113 efficacy profile compares favorably to the efficacy of Nystatin, a current standard of care for topical treatment of oral Candidiasis. The most advanced of three candidates is a peptide therapeutic, PAC-G31P, which is currently being investigated in preclinical studies for its potential to treat inflammatory disease.


Pacgen Biopharmaceuticals - Product Pipeline: PAC 113

The growth of this market and demand for effective anti-fungals is driven by a rising incidence of immunocompromised patients populations including individuals with HIV, cancer, asthma and diabetes, among others. Candida albicans is the most common fungal pathogen among immune-compromised, hospitalized patients, accounting for roughly 50-60% of all bloodstream fungal isolates.